image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 1.33
-5 %
$ 144 M
Market Cap
-0.78
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ACRS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.33 USD, Aclaris Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ACRS stock under the base case scenario is HIDDEN Compared to the current market price of 1.33 USD, Aclaris Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ACRS stock under the best case scenario is HIDDEN Compared to the current market price of 1.33 USD, Aclaris Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ACRS

image
$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
18.7 M REVENUE
-40.09%
-142 M OPERATING INCOME
-45.79%
-132 M NET INCOME
-49.26%
-20.1 M OPERATING CASH FLOW
74.37%
-69.8 M INVESTING CASH FLOW
-150.95%
74.5 M FINANCING CASH FLOW
179.10%
9.21 M REVENUE
111.94%
-99.7 M OPERATING INCOME
-851.91%
-96.6 M NET INCOME
-1172.77%
-8.94 M OPERATING CASH FLOW
-40.63%
-88.7 M INVESTING CASH FLOW
-3174.35%
74.6 M FINANCING CASH FLOW
338900.00%
Balance Sheet Aclaris Therapeutics, Inc.
image
Current Assets 126 M
Cash & Short-Term Investments 114 M
Receivables 318 K
Other Current Assets 12 M
Non-Current Assets 94.4 M
Long-Term Investments 0
PP&E 1.01 M
Other Non-Current Assets 93.4 M
51.56 %5.46 %42.38 %Total Assets$220.3m
Current Liabilities 31.6 M
Accounts Payable 4.69 M
Short-Term Debt 0
Other Current Liabilities 26.9 M
Non-Current Liabilities 33.2 M
Long-Term Debt 0
Other Non-Current Liabilities 33.2 M
7.24 %41.54 %51.22 %Total Liabilities$64.8m
EFFICIENCY
Earnings Waterfall Aclaris Therapeutics, Inc.
image
Revenue 18.7 M
Cost Of Revenue 2.79 M
Gross Profit 15.9 M
Operating Expenses 158 M
Operating Income -142 M
Other Expenses -9.87 M
Net Income -132 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)19m(3m)16m(158m)(142m)10m(132m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
85.09% GROSS MARGIN
85.09%
-758.18% OPERATING MARGIN
-758.18%
-705.48% NET MARGIN
-705.48%
-84.90% ROE
-84.90%
-59.94% ROA
-59.94%
-75.20% ROIC
-75.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Aclaris Therapeutics, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -132 M
Depreciation & Amortization 807 K
Capital Expenditures -121 K
Stock-Based Compensation 10.9 M
Change in Working Capital 10.9 M
Others 105 M
Free Cash Flow -20.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Aclaris Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for ACRS of $6 , with forecasts ranging from a low of $3 to a high of $8 .
ACRS Lowest Price Target Wall Street Target
3 USD 125.56%
ACRS Average Price Target Wall Street Target
6 USD 351.13%
ACRS Highest Price Target Wall Street Target
8 USD 501.50%
Price
Max Price Target
Min Price Target
Average Price Target
8877665544332211May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Aclaris Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
1.5 M USD 1
3-6 MONTHS
1.03 M USD 1
6-9 MONTHS
4.56 M USD 1
9-12 MONTHS
7. News
Aclaris Therapeutics to Participate in Two March Healthcare Conferences WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in March. On Tuesday March 11, 2025, at 3:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Leerink Partners Global Healthcare Conference in Miami, Florida. globenewswire.com - 1 month ago
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.30 per share a year ago. zacks.com - 1 month ago
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases. globenewswire.com - 2 months ago
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board (SAB), which initially includes experts in the field of pulmonology. These include Marianne Mann, M.D. globenewswire.com - 2 months ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris' Board of Directors (the Committee) granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 new employee under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”).  The stock options and restricted stock units were granted as inducements material to the new employee becoming an employee of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4). globenewswire.com - 3 months ago
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy HC Wainwright & Co. analyst Raghuram Selvaraju upgraded Aclaris Therapeutics Inc ACRS from Neutral to Buy and a price target of $20. The stock gained after the rerating. benzinga.com - 3 months ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective December 2, 2024, the Compensation Committee of Aclaris' Board of Directors (the “Committee”) granted nonstatutory stock options to purchase an aggregate of 251,000 shares of its common stock and 73,000 restricted stock units to 4 new employees under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). In addition, also effective December 2, 2024, the Committee granted Hugh Davis, Ph.D, Aclaris' new President and Chief Operating Officer, nonstatutory stock options to purchase 375,000 shares of its common stock and 107,000 restricted stock units under the 2024 Inducement Plan. globenewswire.com - 4 months ago
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York. A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris' website, www.aclaristx.com. globenewswire.com - 4 months ago
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments On Monday, Aclaris Therapeutics, Inc.  ACRS entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R. benzinga.com - 5 months ago
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502. zacks.com - 5 months ago
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed $900M with tiered single digit sales royalty Aclaris Therapeutics will be responsible for development and commercialization of BSI-045B, a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R  worldwide (excluding Greater China) NEWARK, Del. and NANJING, China , Nov. 18, 2024 /PRNewswire/ -- Biosion, Inc. (Biosion), a global R&D stage biotechnology company, today announced that it has entered into an exclusive license agreement with Aclaris Therapeutics (NASDAQ: ACRS) for worldwide rights (excluding Greater China) to BSI-045B, a potential First-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R. prnewswire.com - 5 months ago
Aclaris Therapeutics Announces $80 Million Private Placement WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 million. The private placement is expected to close on or about November 19, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com - 5 months ago
8. Profile Summary

Aclaris Therapeutics, Inc. ACRS

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 144 M
Dividend Yield 0.00%
Description Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Contact 640 Lee Road, Wayne, PA, 19087 https://www.aclaristx.com
IPO Date Oct. 6, 2015
Employees 61
Officers Dr. Neal S. Walker D.O., M.D. Co-Founder, Chief Executive Officer & Chairman Mr. Steve Tucker Senior Vice President of Project Leadership Dr. Joseph Monahan Ph.D. Chief Scientific Officer Mr. Ajay Aggarwal M.B.A., M.D. Senior Vice President of Clinical Development Dr. Jon Jacobsen Ph.D. Senior Vice President of Chemistry Mr. Matthew Rothman J.D. General Counsel & Corporate Secretary Dr. Hugh M. Davis Ph.D. President, Chief Operating Officer & Director Dr. Steven Knapp M.S. Pharm.D. Executive Vice President, Regulatory Affairs & Quality Assurance Mr. Kevin Balthaser Chief Financial Officer Mr. James Loerop Chief Business Officer